Market Assessment, Diabetic Macular Edema/Diabetic Retinopathy Current Treatment US 2016 Report

Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug classes in Europe since 2011. Although laser photocoagulation has long been the standard of care for patients with the most advanced stages of DR, recent clinical trial results suggest that intravitreal pharmacotherapy injections may be effective treatment for this broader patient population as well. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the United States and EU5 markets for DR and DME. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment | EU detailed, expanded analysis offers a snapshot of how ophthalmologists in the EU5 are currently treating DR and DME patients, with a particular focus on use of intravitreal vascular endothelial growth factor (VEGF) inhibitors and intravitreal corticosteroid implants, as well as insight into the factors driving such prescribing habits.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Diabetic Macular Edema/Diabetic Retinopathy | Current Treatment | US | 2016

Related Market Assessment Reports

Alopecia – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)

Diabetic Nephropathy – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Acute Myeloid Leukemia – Unmet Need – Detailed, Expanded Analysis: First-Line Intensive-Induction-Eligible Acute Myeloid Leukemia (US/EU)

Nonalcoholic Steatohepatitis – Unmet Need – Detailed, Expanded Analysis (US/EU)

Multiple Sclerosis – Geographic Focus: China – Multiple Sclerosis: China In-Depth (China)